Axatilimab for Preventing Graft Versus Host Disease in Cancer

This trial tests whether axatilimab, when added to standard treatments, can better prevent graft versus host disease (GVHD) in patients who have received a stem cell transplant for blood cancer. GVHD occurs when the transplanted cells attack the recipient's body, causing symptoms like skin rash and yellowing eyes. The trial compares axatilimab to a placebo to determine which is more effective in preventing GVHD. Suitable patients have a planned stem cell transplant for blood cancer and are receiving stem cells from a matched donor. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial information does not specify if you need to stop taking your current medications. However, it mentions that certain treatments like chemotherapy and radiation therapy should not be received within two weeks before joining, unless they are part of the pre-transplant conditioning. It's best to discuss your specific medications with the trial team.

Research has shown that axatilimab is generally safe for people with chronic graft-versus-host disease (cGVHD). Earlier studies confirmed the consistent safety of axatilimab, with no new or unexpected side effects. The side effects observed were similar to those seen previously. Most patients tolerated the treatment well, and any side effects typically improved over time. Overall, based on current data, axatilimab appears to be a safe option.¹²³⁴⁵

Unlike the standard of care for preventing Graft Versus Host Disease (GVHD), which typically includes drugs like cyclophosphamide, tacrolimus, and mycophenolate mofetil, axatilimab offers a unique approach. Most current treatments work to suppress the immune system broadly, but axatilimab targets the CSF-1 receptor, which plays a role in the behavior of certain immune cells involved in GVHD. This targeted action is what excites researchers because it could mean more effective prevention of GVHD with potentially fewer side effects. Additionally, axatilimab is administered intravenously every two weeks, which might offer a more convenient schedule compared to some existing therapies that require daily dosing.

Research has shown that axatilimab yields promising results for treating chronic graft-versus-host disease (cGVHD). In earlier studies, axatilimab helped 58% to 65% of patients with cGVHD, meaning more than half saw their symptoms improve. This treatment has been effective for patients who tried other therapies without success. In this trial, participants in certain arms will receive axatilimab combined with standard-of-care GVHD prophylaxis. Axatilimab targets specific proteins in the body to prevent the immune system from attacking healthy cells, which may help prevent GVHD from developing.²⁴⁵⁶